Pembrolizumab plus lenvatinib for ovarian cancer that returned
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have confirmed epithelial ovarian cancer (excluding low-grade tumors and mucinous type).
- You are not pregnant or breastfeeding, and if you could get pregnant you agree to effective birth control during treatment and for at least 120 days after the last dose.
- Your cancer has measurable tumors on scans, and your overall day-to-day functioning is good (ECOG 0–1).
- Your cancer is “platinum-sensitive” and came back no earlier than 6 months after finishing prior platinum treatment (or certain prior maintenance treatments).
- You had 0 to 1 chemotherapy treatment phase for the recurrent setting (or up to 1–2 total lines including the first-line treatment) and your time without treatment was more than 6 months for each line.
- You can provide a tumor sample (archived tissue or a new biopsy) from a spot that has not been previously irradiated.
- Your blood pressure and organ blood test results are controlled/adequate for study treatment, as judged by the team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.